Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Visual Plasticity Following Brain Lesions

Vision Improvement Through Behavioral Rehabilitation And Neuroplasticity Training

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss resulting from damage to the post-chiasmatic visual pathways. It aims to investigate whether transcranial random noise stimulation (tRNS) combined with perceptual learning-based training has potential for improving visual impairments.

Who May Be Eligible (Plain English)

A. Stroke, brain tumor, or traumatic brain injury patients Who May Qualify: 1. At least 18 years of age. 2. Capable of providing willing to sign a consent form and complying with study procedures. 3. Unilateral or bilateral focal brain damage causing loss of vision. 4. At least three months post-stroke or traumatic brain injury, or a stable brain tumor within the past year. Who Should NOT Join This Trial: 1. Severe CNS diseases or disorders unrelated to the focal lesion, which could interfere with study results. 2. Severe mental health challenges that could interfere with study results, or current or recent (within the past 6 months) drug or alcohol abuse or addiction as defined by DSM-5. 3. Vision loss resulting from ocular disease or disorder. B. Healthy volunteers (age-matched controls): Who May Qualify: 1. At least 18 years of age. 2. Capable of providing willing to sign a consent form and complying with study procedures. Who Should NOT Join This Trial: 1. Any CNS diseases or psychiatric disorders (e.g., epilepsy, schizophrenia) that would interfere with study results. 2. Previous head injury. 3. Present or past (within past 6 months) drug or alcohol abuse or addiction based on DSM-5. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
A. Stroke, brain tumor, or traumatic brain injury patients Inclusion Criteria: 1. At least 18 years of age. 2. Capable of providing informed consent and complying with study procedures. 3. Unilateral or bilateral focal brain damage causing loss of vision. 4. At least three months post-stroke or traumatic brain injury, or a stable brain tumor within the past year. Exclusion Criteria: 1. Severe CNS diseases or disorders unrelated to the focal lesion, which could interfere with study results. 2. Severe mental health challenges that could interfere with study results, or current or recent (within the past 6 months) drug or alcohol abuse or addiction as defined by DSM-5. 3. Vision loss resulting from ocular disease or disorder. B. Healthy volunteers (age-matched controls): Inclusion Criteria: 1. At least 18 years of age. 2. Capable of providing informed consent and complying with study procedures. Exclusion Criteria: 1. Any CNS diseases or psychiatric disorders (e.g., epilepsy, schizophrenia) that would interfere with study results. 2. Previous head injury. 3. Present or past (within past 6 months) drug or alcohol abuse or addiction based on DSM-5.

Treatments Being Tested

DEVICE

transcranial random noise stimulation (tRNS)

Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: 1 mA current intensity, with a frequency range of 101-640 Hz.

DEVICE

Sham Stimulation

Stimulation location: bilateral human middle temporal complex (hMT+). Stimulation parameters: Ramp up stimulation at 1mA with a frequency range of 101-640Hz for the first 30 seconds followed by no current for the remainder of the duration.

BEHAVIORAL

Perceptual learning-based training

A motion discrimination task, judging the global direction of moving dot stimuli with two different coherence levels.

Locations (1)

Georgetown University Medical Center
Washington D.C., District of Columbia, United States